NICE Guidance - February 2023
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of February 2023. This month there are two Guidelines that impact upon primary care.
The Cardiovascular disease: risk assessment and reduction, including lipid modification guideline has been updated. It covers the assessment and care of adults who are at risk of or who have cardiovascular disease. This update adds a new recommendation on aspirin for primary prevention of CVD. Despite media coverage last month that the threshold for treatment may be lowered this update has made no changes to treatment thresholds.
The Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management guideline has been published. It covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. For symptom control it is recommended to follow the recommendations in the NICE guideline on Gastro-oesophageal reflux disease and dyspepsia in adults.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « CKS Updates - January 2023 | Drug Safety Update - February 2023 » |
Leave a Comment